Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IAPETUS: Irpagratinib + Atezolizumab + Bevacizumab in Advanced/Unresectable HCC
NCT07010497Phase 2Recruiting
- Sponsor
- Asan Medical Center
- Start
- Mar 2026
- Primary completion
- Mar 2029
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of irpagratinib in hepatocellular carcinoma (HCC), sponsored by Asan Medical Center. Primary endpoints: Incidence of Dose-Limiting Toxicities at 3 weeks and Objective Response Rate at 21 months. Started Mar 2026; status: recruiting.
02
Drugs
irpagratinib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT07010497.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07010497.